Work

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

Year: 2019

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-019-00797-1

Authors: Hao Xie, Jun Yin, Manisha H. Shah, Michael E. Menefee, Keith C. Bible, Diane Reidy-Lagunes, Madeleine A. Kane, David I. Quinn, David R. Gandara, Charles Erlichman, Alex A. Adjei

Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, United States Food and Drug Administration, Memorial Sloan Kettering Cancer Center, University of Colorado Anschutz, USC Norris Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center

Language: English

Topic: Adrenal and Paraganglionic Tumors

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Cancer Center Support Grant, Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN, The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network, University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)

OpenAlex ID: W2953447885

FWCI: 3.613

Cites: 33

Cited by: 31

Related to: 10